Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Feature|Articles|June 2, 2026
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
Author(s)Maggie L. Shaw
Fact checked by: Giuliana Grossi
Trauma after cancer is underdiagnosed and often persists into survivorship, with experts urging trauma-informed screening in oncology care.
Advertisement
Advertisement
A cancer diagnosis does not end when treatment does. For a significant portion of patients, the psychological distress it triggers can persist well into survivorship, often going unrecognized and untreated and occurring at any point following a diagnosis.1 Research shows the prevalence can range between 3% and 33%.2-6
Related to this article
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Advertisement
Advertisement